{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T23:08:35Z","timestamp":1768864115146,"version":"3.49.0"},"reference-count":67,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anti-infective Therapy"],"published-print":{"date-parts":[[2025,12,2]]},"DOI":"10.1080\/14787210.2025.2606870","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T15:10:43Z","timestamp":1767798643000},"page":"1163-1172","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating long-acting injectable HIV treatment: an update on cabotegravir and rilpivirine"],"prefix":"10.1080","volume":"23","author":[{"given":"Gabriele","family":"Loi","sequence":"first","affiliation":[{"name":"Vita-Salute San Raffaele University","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University","place":["Milan, Italy"]},{"name":"IRCCS San Raffaele Scientific Institute","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0900-5639","authenticated-orcid":false,"given":"Camilla","family":"Muccini","sequence":"additional","affiliation":[{"name":"IRCCS San Raffaele Scientific Institute","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"e_1_3_4_3_1","unstructured":"UNAIDS. Global HIV & aids statistics - 2025. Fact sheet. [cited 2025 Nov 13]. Available from: https:\/\/www.unaids.org\/sites\/default\/files\/2025-07\/2025_Global_HIV_Factsheet_en.pdf"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(05)70135-5"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30066-8"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2016.03.004"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1600693"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f9b67a"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13111798"},{"key":"e_1_3_4_10_1","unstructured":"EACS guidelines version 12.1 \u2013 October 2023. [cited 2025 Nov 13]. Available from: https:\/\/eacs.sanfordguide.com\/"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/2325958220985665"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-014-0142-1"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-020-03055-1"},{"key":"e_1_3_4_14_1","unstructured":"European Medicines Agency. ViiV Healthcare rekambys \u2013 product information. [cited 2025 Nov 13]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rekambys-epar-product-information_en.pdf"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1909512"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904398"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab324"},{"key":"e_1_3_4_18_1","unstructured":"ViiV Healthcare. Phase 1 clinical trial findings of a cabotegravir LA formulation. Press release. 2024 [cited 2025 Nov 13]. Available from: https:\/\/viivhealthcare.com\/en-us\/media-center\/news\/press-releases\/2024\/march\/cabotegravir-long-acting-injectable\/"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000670"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf135"},{"key":"e_1_3_4_21_1","unstructured":"Colson AE Crofoot GE Ruane PJ et al. Oral weekly islatravir plus lenacapavir in virologically suppressed people with HIV-1: 96\u00a0week outcomes from a phase 2 study. PS15.5.LB. EACS 2025. 2025 Oct 15\u201318."},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2024.2305130"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101016"},{"key":"e_1_3_4_24_1","unstructured":"MERCK. Merck to initiate phase 3 trials for investigational once-monthly HIV prevention pill. Press release. 2025 [cited 2025 Nov 13]. Available from: https:\/\/www.merck.com\/news\/merck-to-initiate-phase-3-trials-for-investigational-once-monthly-hiv-prevention-pill\/"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123110"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf222"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26490"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506110"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.115009"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00051-6"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2563"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.24543"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000168"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2023.2178300"},{"key":"e_1_3_4_35_1","unstructured":"NCBI PubChem. Cabotegravir compound summary. [cited 2025 Nov 13]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Cabotegravir"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2020.06.003"},{"key":"e_1_3_4_37_1","unstructured":"European Medicines Agency. ViiV Healthcare vocabria \u2013 product characteristics. [cited 2025 Nov 13]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vocabria-epar-product-information_en.pdf"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105427"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf019"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01005-1"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz504"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac901"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm040840e"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2022.2081153"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711209105"},{"key":"e_1_3_4_46_1","unstructured":"EDURANT \u2013 FDA drug label. [cited 2025 Nov 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202022s000lbl.pdf"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00899-16"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16154"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1086\/508873"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00152-8"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31917-7"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32666-0"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30340-4"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00136-4"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(24)00344-8"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae326"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13647"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae308"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-023-00890-2"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(24)00269-8"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100793"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf184"},{"key":"e_1_3_4_63_1","unstructured":"HHS Panel on Antiretroviral Guidelines. 2024 [cited 2025 Nov 13]. Available from: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.2985"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.7326\/M23-0788"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae500"},{"key":"e_1_3_4_67_1","unstructured":"CADTH Canadian drug Expert committee \u2013 CAB\/RPV recommendation. [cited 2025 Nov 13]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK566624\/"},{"key":"e_1_3_4_68_1","unstructured":"Australian Government TGA \u2013 CABENUVA. [cited 2025 Nov 13]. Available from: https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent=&id=CP-2021-PI-01236-1&d=20251113172310101"},{"key":"e_1_3_4_69_1","unstructured":"Swiss Agency for therapeutic products \u2013 VOCABRIA. [cited 2025 Nov 13]. Available from: https:\/\/www.swissmedic.ch\/swissmedic\/it\/home\/chi-siamo\/pubblicazioni\/public-summary-swiss-par\/public-summary-swiss-par-vocabria.html"}],"container-title":["Expert Review of Anti-infective Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14787210.2025.2606870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T10:34:54Z","timestamp":1768818894000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14787210.2025.2606870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":67,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,2]]}},"alternative-id":["10.1080\/14787210.2025.2606870"],"URL":"https:\/\/doi.org\/10.1080\/14787210.2025.2606870","relation":{},"ISSN":["1478-7210","1744-8336"],"issn-type":[{"value":"1478-7210","type":"print"},{"value":"1744-8336","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-09-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}